Kimford Meador, AAN 2021: Preliminary findings of the MONEAD Study
It was a great pleasure to meet with Kimford Meador (Stanford University, Stanford, CA, USA) to discuss the aims, design and preliminary findings from the MONEAD study, and what these results mean for treatment of epilepsy in pregnant women.
The abstract entitled: ‘Fetal Antiseizure Medication Effects on Neuropsychological Outcomes at Age 3 Years in the MONEAD Study’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- What were the aims and design of the MONEAD study? (0:12)
- What were the preliminary findings of the study? (2:50)
- If the final results are consistent with these early findings, what recommendations would you give to pregnant women with epilepsy? (4:36)
- What unanswered questions remain? (7:16)
Disclosures: Kimford Meador has received grants from NIH/NINDS 2U01-NS038455-11A1, NIH/NINDS R01NS088748-01, Medtronics; Eisai Inc., and Sunovion Pharma; and has been a consultant for the Epilepsy Consortium, Eisai, GW Pharmaceuticals, Medtronics, NeuroPace, Novartis, Supernus, Upsher Smith Labs, UCB Pharma, and Vivus Pharma. Clinical income: EEG procedures and patient care.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
